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Aim: To compare the economic value of EDWARDS INTUITY Elite™ (EIE) valve system 
for rapid-deployment aortic valve replacement (RDAVR) in a full sternotomy (FS) 
approach (EIE-FS-RDAVR) versus FS-AVR using conventional stented bioprosthesis. 
Data & methods: A simulation model to compare each treatment’s 30-day inpatient 
utilization and complication rates utilized: clinical end points obtained from the 
TRANSFORM trial patient subset (EIE-FS-RDAVR) and a best evidence review of the 
published literature (FS-AVR); and costs from the Premier database and published 
literature. Results: EIE-FS-RDAVR costs $800 less than FS-AVR per surgery episode 
attributable to lowered complication rates and utilization. Combined with the 
lower mortality, EIE-FS-RDAVR was a superior (dominant) technology versus FS-AVR. 
Conclusion: This preliminary investigation of EIE-FS-RDAVR versus conventional FS-
AVR found the EIE valve offered superior economic value over a 30-day period. Real-
world analyses with additional long-term follow-up are needed to evaluate if this 
result can be replicated over a longer timeframe.
First draft submitted: 15 September 2016; Accepted for publication: 27 January 2017; 
Published online: 4 April 2017
Keywords:  aortic  valve  replacement  •  cost  evaluation  •  full  sternotomy  •  INTUITY  •  rapid 
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Approximately 67,500 surgical aortic valve 
replacement (AVR) procedures are per-
formed annually in the USA for treating 
symptomatic aortic stenosis [1]. Conven-
tional AVR performed via full sternotomy 
(FS-AVR) has been the gold standard since 
the 1960s and has proven to be safe and 
effective over time [2]. However, since a min-
imally invasive surgical (MIS) approach was 
first reported in mid-1990s, multiple stud-
ies reported several lower trauma-related 
benefits including decreased postoperative 
pain and ventilation time, less blood loss, 
faster sternal stability and recovery, cos-
metic advantages and quicker discharge 
[3–5]. Despite these advantages, MIS-AVR 
has not gained widespread clinical applica-
tion [6]. This has been partly attributed to 
the technically more challenging nature of 
accessing and deploying a prosthetic aor-
tic valve through a smaller incision. The 
increased complexity may prolong proce-
dural times [4], which may increase major 
postoperative morbidity and mortality [7], 
thus reducing the benefits of the MIS 
approach [2]. Because MIS procedural effi-
ciency has yet to be mastered by the general 
cardiovascular surgeon population, FS-AVR 
has remained the most frequently performed 
approach given its ample visibility and 
e xposure to the vessels.
Advancements in bioprosthetic valve 
design led to rapid deployment AVR 
(RDAVR). One such technology is the 
recently US FDA-approved EDWARDS 
INTUITY Elite™ (EIE) valve system 
(Edwards Lifesciences LLC, CA, USA). The 
valve system consists of: a trileaflet bovine 
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Figure 1. Model scaffold – clinical outcomes. 
†The MISAVR and CAVR cohorts have the same clinical outcomes as the MIS-RDAVR arm. 
EIE-FS-RDAVR: Edwards INTUITY Elite full sternotomy rapid deployment aortic valve replacement; FS-AVR: Full 
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pericardial bioprosthesis; a delivery system including 
a cloth-covered skirt frame at the inflow aspect; and 
a balloon catheter to deploy the valve after placement 
within the aortic annulus. Unlike the conventional 
valves that require a time-consuming implantation 
of 12–16 pledgeted sutures, EIE valves involve place-
ment of three equidistant figure-of-eight or mat-
tress guiding nonpledgeted sutures. Found to be safe 
and efficacious in both the MIS-AVR and FS-AVR 
approaches, the EIE Valve system was found to facili-
tate lower cross-clamp, bypass and operative times 
compared with their FS-AVR’s counterparts. This, in 
turn, may be associated with the potential benefits of 
shorter hospital stays, faster recovery and improve-
ments in morbidity and mortality outcomes [8]. With 
rapidly escalating healthcare expenditures, and the 
US hospitals’ and policymakers’ increased focus on 
cost containment while enhancing and improving 
patient care, it is vital to formally assess the economic 
impact and comparative value of innovations such as 
the EIE valve system. Hence, this study performed 
an economic evaluation of the EIE valve system’s 
RDAVR via FS (EIE-FS-RDAVR) versus the FS-
AVR approach involving standard prosthetic aortic 
valves.
Data & methods
Using TreeAge Pro 2015 analysis software (TreeAge 
Software Inc., MA, USA), we constructed and ana-
lyzed a cost simulation model comparing the inpatient 
utilization and complication treatment costs for EIE-
FS-RDAVR versus FS-AVR. Figures 1 & 2 elaborate on 
the model scaffold and the clinical and economic out-
comes examined for each of the two procedure arms, 
respectively. The model focuses on the surgery hos-
pitalization and a subsequent 30-day follow-up time 
horizon. The model was rebuilt using Microsoft Excel 
for validation purposes.
Clinical end points
Clinical end point estimates for the EIE-FS-RDAVR 
arm were derived from the 30-day outcomes of the sub-
set of 211 TRANSFORM™ trial patients undergoing 
an isolated FS-AVR with the EIE valve system. The 
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Figure 2. Model scaffold – expected cost calculations. 
†Costs to the hospital per episode were calculated from the Premier database. Unless otherwise noted, all costs are 
in 2016 US$. 
‡[9]; §[10]. 
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TRANSFORM trial was a prospective, nonrandom-
ized, multicenter trial that enrolled up to 950 s ubjects 
at 29 centers across the USA.
Clinical end points for the FS-AVR arm were esti-
mated after we conducted a best evidence review of 
the published literature. Thirty-one studies were cho-
sen that satisfied the following inclusion criteria : (1) 
English language publications from 2003–2015; (2) 
adult subjects (≥18 years of age) who received iso-
lated or concomitant FS-AVR; (3) reported one or 
more of the outcomes of interest: cross-clamp, skin-
to-skin and/or operating room times, complications 
(endocarditis, renal failure, stroke, transient ischemic 
attack [TIA], bleeding leading to reoperation, and/or 
postoperation sternal wound infection), ICU and/or 
hospital length of stay (LOS). Studies were excluded 
if they involved : (1) endovascular AVR or transcath-
eter (transapical) AVR surgeries; (2) AVR done in 
conjunction with aortic root replacement; (3) only 
pediatrics; (4) in vitro, animal, or cadaver research; 
(5) percutaneous AVR; (6) valve-in-valve operations 
and (7) case reports, commentaries and editorials. 
Individual parameter estimates obtained from all the 
studies meeting the inclusion criteria (n = 31) were 
then pooled and weighed by their respective sample 
sizes (see Tables 1 & 2). These weighed average esti-
mates were then used in the simulation model as 
parameters for the standard FS-AVR arm. To check 
for clinical comparability of the FS-AVR popula-
tion and the TRANSFORM trial subset, we exam-
ined the demographic and comorbid risk profiles of 
EIE-FS-RDAVR patients in TRANSFORM versus 
the literature-derived cohort. While quite similar on 
the preoperative characteristics, the TRANSFORM 
patients were slightly older and had a higher rate of 
co-morbidities. Average age for the EIE-FS-RDAVR 
TRANSFORM and FS-AVR patients was 73 and 
67 years, respectively. Additionally, TRANSFORM 
patients’ Society of Thoracic Surgeons scores – pre-
dictive of perioperative mortality [11] – were found to 
be higher relative to FS-AVR (2.3 vs 1.5). TRANS-
FORM patients also had a modestly higher percent-
age of patients with prior cardiac surgery (22 vs 17%), 
diabetes (40 vs 19%), hypertension (92 vs 67%), 
peripheral arterial disease (14 vs 9%) and/or renal 
failure (10 vs 7%) versus FS-AVR with the exception 
of NYHA Class III/IV (32.4 vs 41%). Overall, with 
the TRANSFORM cohort being older and sicker 
with a higher proportion of comorbidities and Society 
of Thoracic Surgeons score, any potential bias would 
lead to conservative model estimates when compared 
with FS-AVR (e.g., higher costs).
Cost data
The EIE valve system was estimated to cost an addi-
tional US$3000–6000 over the standard prosthetic 
valves (Edwards Lifesciences LLC, CA, USA). The 
highest price point (US$6000) was used as the base-
line cost estimate keeping in line with the conservative 
approach of the study. Adverse event cost data for this 
analysis were taken from the 2012 Premier hospital 
database to be representative of a hospital perspective. 
The Premier database contains data from approxi-
mately 500 hospitals across the USA involving more 
than 310 million patients who receive treatment each 
year through their healthcare alliance members. It is 
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representative of one in every five discharges in the 
nation and is the nation’s largest hospital-level clini-
cal and financial comparative database. Published lit-
erature estimates were used to populate the resource 
use-related cost estimates. Figure 2 depicts how epi-
sode costs from the Premier database and published 
literature were combined with utilization measures 
and complication rates to obtain expected costs. These 
costs were then converted to 2016 dollars using the 
2016 Medical Care Component of the Consumer 
Price Index.
Incremental costs
The model estimated the incremental cost difference 
between EIE-FS-RDAVR and FS-AVR by account-
ing for the additional cost of the EIE valve (rela-
tive to the standard valve) and the cost differences 
in treating the adverse events of interest. The change 
in life years was estimated as the difference in mor-
tality rate between EIE-FS-RDAVR and FS-AVR 
multiplied by the life expectancy of the individual. 
Consistent with a previous analysis, we assumed an 
average life expectancy of 11 years for surgical AVR 
individuals in this population [42,43]. The Likosky 
study, besides finding comparable long-term survi-
vorships between AVR patients and a general popu-
lation of similar age, also found that this survival 
varied little and was not contingent on the type 
of AVR surgery. Given this evidence, we assumed 
that long-term  survival was identical across the two 
t reatment groups.
Sensitivity analysis
To gauge the robustness of the results, one-way sensi-
tivity analyses were performed by varying the model 
parameters by ± 25% from their baseline values and 
calculating the incremental cost difference between 
EIE-FS-RDAVR and FS-AVR. A tornado diagram 
was generated to visually demonstrate the impact of 
individual model parameter values (Figure 3).
A 5000 trial Monte-Carlo probabilistic sensitivity 
analyses was also performed. For the FS-AVR arm, a 
normal and beta distributions were assumed for the uti-
lization and complication estimates, respectively, based 
on published evidence [44]. The sample-size weighted 
mean and standard deviation will be used as the distri-
bution parameters. Given that there was a single source 
(TRANSFORM trial) for the EIE-FS-RDAVR clinical 
outcomes data, we lacked data on dispersion to help 
generate detailed distributions for this arm. To address 
this issue, we assumed that the EIE-FS-RDAVR 
parameters followed the same distribution as their cor-
responding FS-AVR parameters and had the same stan-
dard deviation as well, with the TRANSFORM trial 
point estimates replacing their corresponding values 
from the FS-AVR arm. Thus, for each parameter in the 
EIE-FS-RDAVR arm, the distribution was shifted to 
the right or left of the distribution for its correspond-
ing FS-AVR parameter, depending on whether its value 
was higher or lower than the FS-AVR value. The pro-
portion of simulated trials for which EIE-FS-RDAVR 
demonstrated economic value (i.e., cost savings or 
cost–effectiveness) versus FS-AVR was estimated.
Table 1. Best evidence literature review summary for full sternotomy (conventional) aortic valve 
replacement.
Model parameters FS-AVR (range) Ref.
Adverse events 
Endocarditis 0.4–4.9 [12,13]




Postoperation wound infection 0–14.3 [2,12–14,16–18,21–22,24–27,30–31,33–37]
Mortality rate
30-day mortality 1–4.9 [2,13,16,20,25,27–28,34]
Utilization measures
Operating room (minutes) 146.4–286.9 [2,14–15,20,27,32,35–38]
Operating room CCT (minutes) 33.5–89.5 [2,12–18,20–21,24–40]
ICU days 0.92–5.66 [12,14,16,18–20,22–23,27–28,31–38,41]
Hospital ward days 6–17.7 [12–13,18,22–23,27–28,31–38,41]
FS-AVR: Full sternotomy (conventional) aortic valve replacement; ICU: Intensive care unit; TIA: Transient ischemic attack.
www.futuremedicine.com 297future science group
Economics of rapid deployment AVR via full sternotomy    Research Article
Results
Adverse events & mortality rates
Adverse event and mortality rates for each of the 
three procedures are provided in Table 2. Compared 
with FS-AVR, EIE-FS-RDAVR had lower rates of 
endocarditis (0 vs 1.2%), stroke (0.6 vs 2.1%), reop-
erations (0.6 vs 4.0%), postoperative wound/thoracic 
infection (0.6 vs 2.7%) and mortality (0 vs 2.8%). In 
contrast, EIE-FS-RDAVR had slightly higher rates of 
renal c omplications (4.4 vs 4.3%) and TIAs (1.1 vs 
0.8%).
Hospital resource utilization
Utilization measures by procedure type are also pro-
vided in Table 2. Time spent in the operating room 
and cross-clamp time were lower for EIE-FS-RDAVR 
(168.7 and 50.3 min) in comparison to FS-AVR (198.4 
and 68.4 min). ICU days were marginally higher for 
the EIE-FS-RDAVR versus FS-AVR (2.9 vs 2.5 days), 
but hospital ward (length of stay) days were lower (7.2 
vs 9.9 days).
Expected costs
EIE-FS-RDAVR costs US$800 less per surgery than 
FS-AVR while generating more life years gained 
(Table 3). As such, EIE-FS-RDAVR may be considered 
a superior (dominant) technology relative to FS-AVR.
Sensitivity analysis
One-way sensitivity analyses demonstrated that the 
EIE-FS-RDAVR retained its economic value in com-
parison to FS-AVR and that these results were robust. 
These results were found to be most sensitive to hospi-
tal ward days and/or costs and the cost of the EIE valve 
(see Figure 3). In the probabilistic sensitivity analysis, 
cost savings were observed in 52.0% of the Monte 
Carlo simulations, indicating that EIE-FS-RDAVR 
was a dominant treatment strategy. Of the remain-
ing 48.0% of simulations where EIE-FS-RDAVR 
costs were higher than FS-AVR, the incremental cost 
per life year gained (incremental cost–effectiveness 
ratio; ICER) was <$50,000 in 66.4% of the cases and 
<US$100,000 94.8% of the time. Thus, probabilis-
tic sensitivity analysis revealed that EIE-FS-RDAVR 
conferred superior economic value (either dominant 
or cost–effective) in 83.8–97.5% of the simulations, 
depending on the threshold.
Discussion
An estimated 4.4–5.2 million adults (1.8%) in the 
USA have an aortic valve disease diagnosis [45]. Its 
prevalence increases with age, from 2.5% at 75 years to 
8.1% at 85 years [46]. Left untreated, disease progres-
sion is rapid and fatal with a mean survival time of 
only 1.5–3 years past diagnosis [42]. Elective FS-AVR 
performed through FS has been deemed a safe proce-
dure since it carries low morbidity and short/long-term 
mortality rates. Specifically, multiple studies found 
AVR to be associated with favorable long-term survi-
vorship, with average times ranging between 6.2 and 
11.2 years postsurgery depending on age [42,47]. As 
such, AVR (isolated or concomitant with coronary 
Table 2. Adverse events, mortality and utilization by procedure type.
Model parameters EIE-FS-RDAVR FS-AVR
Adverse event rates (%) 
Endocarditis 0 1.2 ± 1.1
Renal complications 4.4 4.3 ± 2.1
Stroke 0.6 2.1 ± 1.4
TIA 1.1 0.8 ± 0.9
Reoperation 0.6 4.0 ± 2.0
Postoperation wound infection 0.6 2.7 ± 1.6
Mortality rate (%)
30-day mortality 0 2.8 ± 1.7
Utilization measures
Operating room (minutes) 168.7 198.4 ± 14.2
Operating room CCT (minutes) 50.3 68.4 ± 8.3
ICU days 2.9 2.5 ± 1.6
Hospital ward days 7.2 9.9 ± 3.1
CCT: Cross-clamp time; EIE-FS-RDAVR: Edwards INTUITY Elite™ full sternotomy rapid deployment aortic valve replacement; FS-AVR: Full 
sternotomy (conventional) aortic valve replacement; ICU: Intensive care unit; TIA: Transient ischemic attack.
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Figure 3. One-way sensitivity analysis results – tornado diagram. 
EIE-FS-RDAVR: Edwards INTUITY Elite™ full sternotomy rapid deployment aortic valve replacement; FS-AVR: Full 
sternotomy (conventional) aortic valve replacement; ICU: Intensive care unit; OR: Operating room; TIA: Transient 
ischemic attack.
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artery bypass graft surgery) remains an effective treat-
ment for this diseased population. However, medical 
and technological advancements have led to improved 
life expectancy culminating in an era of an aging 
population. For instance, septuagenarians and octo-
genarians are projected to double and triple in size, 
respectively, by 2050 from their current numbers [48]. 
Therefore, it is safe to assume that the prevalence of 
aortic valve disease and the subsequent need for AVR 
will grow. New technologies for performing AVR hold 
the possibility of improving safety and outcomes while 
controlling costs. But these technologies must be eval-
uated carefully to understand their potential clinical 
and economic value.
The present study is, to our knowledge, the first eco-
nomic evaluation comparing the value of using EIE-
FS-RDAVR in place of the standard aortic valve via a 
FS-AVR procedure. The results suggest that the EIE-
FS-RDAVR is associated with cost savings of $800 
per surgery (when figured using the high end of the 
incremental cost range) for every hospitalized patient 
within a 30-day follow-up time horizon. While these 
savings can be primarily attributable to the reduced 
LOS and lower complication rates, EIE-FS-RDAVR 
also advances the care of FS-AVR patients by facilitat-
ing a faster deployment. The probabilistic sensitivity 
analysis results indicate that in Monte-Carlo trial sim-
ulations numbering, EIE-FS-RDAVR was either cost-
saving or cost–effective in 83.8% (ICER <US$50,000) 
to 97.5% (ICER <US$100,000) of the cases, thus con-
ferring a superior economic value compared with the 
standard FS-AVR over a 30-day period. Recent surveys 
suggest that the average US retirement age has been ris-
ing modestly over the past few decades [49]. Therefore, 
an earlier hospital discharge in this patient population 
could potentially indicate an accelerated path toward 
recovery, and returning to work time and routine life 
activities and is therefore suggestive of societal ben-
efits that go beyond the costs measured in this study. 
This is of course under the presumption that the cur-
rently observed short-term benefits would persist over a 
l onger follow-up time.
Table 3. Expected costs by procedure type.
Per patient EIE-FS-RDAVR† FS-AVR
Expected costs US$43,568 US$44,368
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Limitations
We acknowledge there are several limitations to the 
current study. Because FS-AVR-specific outcomes 
were not available from the TRANSFORM trial itself, 
the comparative parameters were generated from the 
published literature and represented a mix of con-
trolled trial and real-world experiences, a broader 
range of settings and with more experience on average. 
Furthermore, owing to the literature-driven compari-
son, it was difficult to account for any patient selection 
biases and other unmeasured differences. For example, 
the use of mechanical valves (while unlikely in these 
age cohorts) would have necessitated the use of peri-
operative anticoagulation therapy which may have 
subsequently impacted the incidence rates of TIA and 
stroke. While the downstream impact of this argu-
ment may have had a bidirectional influence on the 
cost comparison, assessing the actual impact of these 
kinds of preoperative differences on our outcomes of 
interest was outside the scope of the current study pro-
tocol. However, the FS-AVR cohort’s overall patient 
characteristics were found to be similar, albeit slightly 
healthier than the TRANSFORM trial study popula-
tion, which may have led to conservative incremental 
cost estimates of EIE-FS-RDAVR. Second, while the 
most common and prevalent adverse events associated 
with AVRs were considered in this analysis, there were 
some potentially infrequent relevant adverse events 
(e.g., pneumonia) that could not be included due to 
data limitations. A randomized, controlled trial com-
paring EIE-FS-RDAVR with FS-AVR would need to 
be conducted to fully address this concern. In addi-
tion, this economic evaluation can only be deemed as 
a preliminary investigation since it utilized only the 30 
days post-AVR outcomes owing to the paucity of data. 
Further follow-up is needed to explore the durability 
and performance (clinical and economic) of EIE-FS-
RDAVR and to evaluate if the short-term trends are 
replicated over a longer time period.
Conclusion
The EDWARDS INTUITY Elite valve system™ 
rapidly deployed in a FS-AVR procedure appears to 
achieve cost savings and, therefore, superior economic 
value while simultaneously advancing the overall care 
of FS-AVR patients over a 30-day postoperative period. 
The observed cost savings were found to be robust and 
attributable to lower complication rates (e.g., reopera-
tion, postoperative wound infection, stroke and endo-
carditis) and utilization (e.g., cross-clamp and operat-
ing room times, and hospital stay). Additional studies 
and ‘real-world’ analyses with a focus on the long-term 
performance of the valve are required to further under-
stand the potential value of the EIE valve system in this 
procedure. It is essential that these preliminary short-
term trends be evaluated for replication over a longer 
time horizon.
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•	 EDWARDS INTUITY Elite™ full sternotomy rapid deployment aortic valve replacement (EIE-FS-RDAVR) cost per 
each episode of care was US$800 less than FS-AVR.
•	 The observed cost savings were attributable to lower complication rates (e.g., reoperation, postoperative 
wound infection, stroke and endocarditis) and utilization (e.g., cross-clamp and operating room times, and 
length of stay) during the 30-day follow-up period.
•	 One-way sensitivity analysis found that the results were most sensitive to hospital stay and/or costs and the 
EIE valve cost.
•	 In the probabilistic sensitivity analysis, EIE-FS-RDAVR was found to be either dominant or cost–effective in 
97.5% of the simulation scenarios.
•	 The TRANSFORM trial’s subpopulation was slightly less healthy than the FS-AVR cohort’s weighted 
demographic and comorbid characteristics which may have led to conservative cost estimates in the current 
analysis.
•	 With the older adult population projected to double and triple in size in the next few decades, the need for 
AVR is expected to grow. As such, cost-saving technologies need to be prioritized to curtail the escalating 
healthcare expenditures.
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